The FDA warns Beckman Coulter on multiple quality issues at its California manufacturing plant, including issues related to its Class 1 recall of an electrolyte assay in May.

The FDA filed a Warning Letter against Beckman Coulter Inc. (NYSE:BEC) this month, detailing a long list of alleged quality issues surrounding the company's manufacturing facility.
Based on an investigation of Beckman's Brea, Calif.-based facility, the watchdog agency found problems with design validation processes, design change processing procedures, personnel training and reporting and execution systems for corrective and preventative actions, among other complaints.
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth...
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...